PE02.14LB | Functional barriers in the elicitation of broadly neutralizing antibodies against the glycan-V3 site of Env by vaccination | E-poster | Broadly neutralizing antibodies |
PE02.15LB | The near-pan-neutralizing, plasma deconvoluted antibody N49P6 mimics CD4 in its quaternary interactions with the HIV-1 envelope trimer | E-poster | Broadly neutralizing antibodies |
PE02.16LB | Improved potency, breadth, and pharmacokinetics of VRC01-class antibodies for HIV-1 prevention and treatment | E-poster | Broadly neutralizing antibodies |
PE02.17LB | A lineage of exceptionally potent and broad BnAbs with ultralong CDRH3 from vaccinated cows focus low-mutation rate from germline into a globular knob contacting the CD4bs | E-poster | Broadly neutralizing antibodies |
PU02.01 | Subtle variations in HIV-1 subtype C env sequence features obtained from a slow progressing Indian donor and their association with sensitivity to neutralizing antibodies with distinct epitope specificities | Publication Only | Broadly neutralizing antibodies |
PU02.03 | Isolation of new CAP256-VRC26 lineage members reveals determinants of breadth and potency | Publication Only | Broadly neutralizing antibodies |
OA09.03 | Impact of HLA-II associated HIV-1 adaptations on vaccine-induced CD4 T-cell immune responses | Oral Abstract Session | Cellular immunity |
OA09.05LB | Spontaneous in vivo control of HIV replication is underpinned by the cross-clade antiviral potency of HIV-specific CD8 T cells | Oral Abstract Session | Cellular immunity |
OA14.05LB | Impact of HIV kick-and-kill therapy on host epigenetic and transcriptional programs in PBMC, and viral rebound after cART interruption | Oral Abstract Session | Cellular immunity |
OA20.01 | Alternative T cell effector functions are linked to humoral responses to HIV infection | Oral Abstract Session | Cellular immunity |